On November 9, 2023 Ichnos Sciences, a global clinical-stage biotechnology company developing innovative multispecific antibodies for oncology, reported that three abstracts highlighting data on its leading oncology assets have been selected for presentation at the upcoming 65th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition (Press release, Ichnos Sciences, NOV 9, 2023, View Source [SID1234637369]). The meeting will be held December 9-12, 2023, in San Diego, California.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

These abstracts discuss three assets—ISB 2001, ISB 1342 and ISB 1442—each of which have been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma and are currently in global Phase 1 clinical studies. The data to be presented will demonstrate the innovative approach of Ichnos’ proprietary BEAT platform1 to target tumor cells via the engagement of different immune cell subtypes. This approach holds promise to be a curative therapy for patients experiencing relapsed or refractory multiple myeloma who need new treatment options.

"Ichnos’ work is built on a foundation of believing a cure is attainable and recognizing that there is a wide space in oncology for original thinking when it comes to developing efficient, disease-specific treatments," said Lida Pacaud, M.D., Chief Medical Officer of Ichnos Sciences. "Our scientific platform leverages the power of the human immune system in the fight against cancer, and we are glad to be granted the opportunity to share our data on this approach thus far at the upcoming ASH (Free ASH Whitepaper) Annual Meeting."

Visit the Ichnos Sciences booth (#305) at the ASH (Free ASH Whitepaper) Annual Meeting to learn more about Ichnos’ proprietary BEAT platform, expanding pipeline of assets in hematological and solid tumor malignancies, partnership opportunities and more.

More information about Ichnos presentations is detailed below:

Title Details (All in Pacific Time)
Poster Presentation: Trial in Progress: A Phase 1, First-in-Human, Dose Escalation and Dose-Expansion Study of a BCMAxCD38xCD3 Targeting Trispecific Antibody ISB 2001 in Subjects with Relapsed / Refractory Multiple Myeloma (RRMM) Sunday, December 10, 2023, 6:00 PM-8:00 PM
San Diego Convention Center, Halls G-H
Session: 653. Multiple Myeloma: Prospective Therapeutic Trials: Poster II
Publication Number: 3396
Poster Presentation: Dose Escalation of ISB 1342, a Novel CD38xCD3 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM) Sunday, December 10, 2023, 6:00 PM-8:00 PM
San Diego Convention Center, Halls G-H
Session Name: 652. Multiple Myeloma: Clinical and Epidemiological: Poster II
Publication Number: 3339
Poster Presentation: Initial Results From the Dose Escalation Phase1/2 of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM) Monday, December 11, 2023, 6:00 PM-8:00 PM
San Diego Convention Center, Halls G-H
Session Name: 652. Multiple Myeloma: Clinical and Epidemiological: Poster III
Publication Number: 4707

The full ASH (Free ASH Whitepaper) 2023 Annual Meeting abstracts are available for review at: View Source
Follow Ichnos on LinkedIn for more updates throughout the conference.